



11TH AIS 2023

JUNE 22-23, 2023
TOURS, FRANCE

MABimprove
LabEx Tours Montpellier

mabdesign
THE BIOTHERAPY EXPERT

Post-Event Report

OUR STORY

In order to provide to the scientists involved in research on therapeutic antibodies, a comprehensive view about topics of interest for the pharmaceutical industry the LabEx MAbImprove started the **Antibody Industrial Symposium** in 2013.

Here are the previous editions:

1st Antibody Industrial Symposium (AIS2013) - May 28 in Tours, 2013

"Antibody Biosimilars"

2nd Antibody Industrial Symposium (AIS2014) – July 3 in Montpellier, 2014

"MAbDosing"

3rd Antibody Industrial Symposium (AIS2015) – July 2 in Tours, 2015

"MAbDelivery"

4th Antibody Industrial Symposium (AIS2016) – July 4-5 in Montpellier, 2016

"Current and Next Generation Antibody Formats"

5th Antibody Industrial Symposium (AIS2017) – June 27-28 in Tours, 2017

"ADCs – Design & Development for Therapy and Imaging in and beyond Cancer"

6th Antibody Industrial Symposium (AIS2018) – June 25-26 in Montpellier, 2018

"TARGETS FOR MABS: Innovative Approaches for their Discovery & Validation"

7th Antibody Industrial Symposium (AIS2019) – June 24-25 in Tours, 2019

"Harnessing the Immune System with Therapeutic Antibodies"

8th Antibody Industrial Symposium (AIS2020) – November 23-24 2020, Virtual format

"Multispecific Antibodies, Ab-like Molecules & Adoptive Cell Therapy for Fighting Diseases"

9th AIS (AIS2021) – June 22-25 2021, Virtual format

10th AIS(AIS2022) – June 28-29 in Montpellier, 2022 – **ANNIVERSARY EDITION**

11th AIS(AIS2023) – June 22-23 in Tours, 2022 – ***Parallel Tracks on therapeutic Abs and Cell & Gene Therapy***

SAVE THE DATE



Since the 4th edition of AIS2016, MabDesign has joined forces in the organization of this congress, bridging academia and industry. Since 11 years, the AIS has allowed to gather more than **3280+ Participants** from **23 different countries**, **427+ Expert Speakers**, held **2710+ B2B meetings**, presented **97 Pitches**, **231+ posters** and **239 Exhibitors/Sponsors** showcase their latest innovations, in the fields of antibody, cell & gene therapy and other biotherapeutics research and development.

KEY FIGURES


- ✓ **350+** participants from 23 different countries

✓ **300+** BtoB meetings took place


✓ **190+** different organizations present
- ✓ **45** Exhibitors and Sponsors

✓ **49** High-profile Speakers

✓ **51** Poster presentations



WHERE FROM?



2023 SPONSORS & EXHIBITORS



WITH THE SUPPORT OF



2023 INSTITUTIONAL PARTNERS



THE 2023 AGENDA

DAY 1

Thursday, June 22nd 2023

8h00 Registration and welcome coffee

8h45 Welcome Address

9h00 OPENING KEYNOTE LECTURES

Design and Development of Antibody-Drug Conjugates: An Overview of the Progress in the Field and Perspectives on Future Prospects



John Lambert

Former Chief Scientific Officer, ImmunoGen, Inc. (retired 2018)
Honorary Professor, Queen's University Belfast, Northern Ireland
Consultant, Cambridge, Massachusetts, USA
John Lambert Consulting, USA

Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali



Prof. Kassoum Kayentao

University of Sciences, Techniques and Technologies of Bamako (USTTB), Mali

10h00 Coffee Break - Exhibition Hall - B2B Meetings

10h30 Track What we have learnt from Non-Traditional Antibodies formats so far

Current and Next Generation ADCs



Alain Beck

Senior Director

Biologics CMC & Developability, Pierre Fabre, France

Immune stimulant TLR7/8 agonist antibody drug conjugate for the treatment of CEACAM5-expressing tumors



Alexandra Ferrier

Senior Principal Scientist Group Head in Drug Conjugates Medicinal Chemistry
SANOFI, France

Identification and Therapeutic Application of Multispecific Antibodies



Peter Lowe

Director Antibody Engineering

Merus, The Netherlands

Utilizing endocytosis as an ADC biomarker




Anette Weyergang

Senior scientist at the Institute for Cancer Research
Oslo University Hospital, Norway

Track Cell Therapy: new approaches

EVOcells, immune effector cells derived from iPSc for allogeneic therapeutic approaches in immuno-oncology



Michael Esquerré

Vice-President Immuno-Oncology, Immuno-Oncology Therapeutic Area lead

Evotec, France

Life Saving stem Cell Therapy for inflammatory diseases



Danièle Bensoussan

Co-founder

StemInov

PU-PH - Head of Cellular Therapy Unit and Tissue Bank

Cord Blood Bank (UTCT)

Head of a Research Unit

CNRS, France

THE 2023 AGENDA

BEACON® single cell technology and mRNA immunization: A unique combination for antibody discovery against GPCRs and difficult targets



Manuel Pelé
Project Manager
MmAbs, France

Writing the Future of Biologics with Synthetic DNA and High-throughput Antibody Production



Radhar Parmar
Science and technology consultant, biologics - EMEA
Twist Bioscience

12h10 - Lunch break - Exhibition Hall - B2B Meetings

14h00 - **Track Isolating Human Antibodies from the Human Repertoire**

Antibodies from Resilient Individuals: A novel approach for Antibody Drug Discovery



Sandrine Legg
Director of Phenotypic Screening, Research
Alchemab Therapeutics Ltd, UK

Monogenic autoimmunity as a source of antibodies with therapeutic and diagnostic potential



Kai Kisand
University of Tartu, Estonia

Speed up your therapeutics antibody research and production with no-wash immunoassay solutions



Marielle Mazille
EMEA Subject Matter Expert application Team Leader - Life Science Revvity

Comprehensive antigen-specific clonotype discovery in one week



Christophe Fleury
Science & Technology Advisor 10XGENOMICS, France

15h20 - Coffee Break - Exhibition Hall - B2B Meetings

Track Tackling Toxicity of CART Treatments

Joint Forces - Synergizing Microbiota-derived metabolites and Cellular Therapy



Maik Luu
Junior Group Leader and Scientific Project Manager of T2EVOLVE
University Clinic Würzburg, Germany

Preclinical models to assess safety and efficacy of engineered T cells



Emmanuel Donnadieu
Group Leader
Institut Cochin, France

THE 2023 AGENDA

16h10 • Pitch Session : Innovative Approaches and New trend Technologies

Development of a versatile intracellular antibody-based approach for targeted protein degradation



Anaïs Cornebois
PhD student
SANOFI & Centre en Cancérologie de Toulouse (CRCT)

Characterization and optimization of an antibody drug conjugate, Adcitmer, in the treatment of Merkel Cell Carcinoma



Aurélié Drouin
Research Engineer, ISP UMR1282
Université de Tours

The "Cure RA" project: Towards a targeted phagocytosis of ACPA+ B lymphocytes in Rheumatoid Arthritis



Cyril Clavel
Associate professor in Cell Biology
Infinity Inserm UMR1291 - Université Toulouse III

An automation platform for the production and characterization of patient derived monoclonal antibodies focusing on autoimmune neurological disorders



Dominik Stappert
Scientist and Project Manager, CRFS-LAT
German Center for Neurodegenerative Diseases (DZNE)

A new platform for the high-throughput screening of soluble full-length IgG libraries



Esteban Lebrun
Post-doctoral researcher
INRAE - Micalis Institute

Intra-Domain Cysteines (IDC), a New Strategy for the Development of Original Antibody Fragment-Drug Conjugates (FDCs)



Louis Jolivet
PhD student
ISP UMR1282, Université de Tours

Extracellular vesicles: a powerful tool for membrane protein studies



Vincent Delauzun
Research Scientist
CYTOBODX

17h30 • POSTER Presentation - WINE & CHEESE

20h00 • Cocktail Gala Dinner - Château Belmont

THE 2023 AGENDA

DAY 2

Friday, June 23rd 2023

8h00

Welcome coffee

9h00

OPENING KEYNOTE LECTURES

Sotatercept for the treatment of pulmonary arterial hypertension



Prof. Marc Humbert
Professor of Respiratory Medicine
Université Paris-Saclay, France

CAR T cell therapy in autoimmune disease



Prof. Dr. Georg Schett
Head of Department of Medicine 3 - Rheumatology and Immunology and Vice President Research
Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Germany

10h00

Coffee Break - Exhibition Hall - B2B Meetings

10h30

Track Biotherapeutics in Clinic: when the clinic is reshuffling the cards

Approved indications of CAR-T cells in Onco-hematology and immunomonitoring of patients receiving CAR-T cells



Marie-Thérèse Rubio
Professor in clinical immunology, stem cell transplantation, immunotherapy
CHRU Nancy, France

Counter-intuitive lessons from the clinical experience in chronic inflammatory diseases



Thierry Schaevebeke
Head of the Rheumatology Department and Coordinator of Clinical Research
CHU Bordeaux, France

Novel insights into pathophysiology and further differences between AQP4-IgG- and MOG-IgG-associated diseases



Simone Mader
Junior Group Leader
Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center Ludwig-Maximilians University Munich, Germany

Multi-armed oncolytic vectors for targeted modification of the tumor micro-environment




Eric Quémeneur
Executive VP, CSO
Transgene, France

Accelerating therapeutic development using advanced protein and

Track Overcoming Bioprocessing Challenges to go into Clinic

Session I

Strategies to overcome common challenges in the production and characterization of bi- and multi-specific antibodies



Sabrina Vollers
Senior Team Leader, Head of Functional and PK Bioanalytic
Ichno Sciences, Switzerland

From Discovery to Clinic: Overcoming Bioprocessing Challenges in Icosagen's Humanization of New Drug Candidates



Paule Hermet
Researcher
ICOSAGEN, Estonia

Bioluminescent platform technology to drive antibody discovery and development



Jamison Grailer
Sr. Research Scientist, Team Leader of the R&D cell-based bioassay development group
PROMEGA

MAM studies on benchtop MS instruments to boost QbD process development and high-throughput testing of major CQAs in a regulated environment



Géry Van Vyncht
Scientific Director, R&D and Innovation
Quality Assistance, Belgium

THE 2023 AGENDA

Accelerating therapeutic development using advanced protein and antibody development platforms



Yu-Chih Lin
Ph.D, Technical Specialist
Sino Biological

Biosafety & DS Characterisation



Luc-Alain Savoy
Global Head of Biologics
SGS, Switzerland

Innovative Surface Chemistry for Reliable Antibody Characterization and Epitope Binning



Claude Nogues
Scientific Director & Co-Founder
Kimialys

12h00

Lunch break - Exhibition Hall - B2B Meetings

14h00

Track MAbs Immunopharmacology, what's new?

A new COST Action: European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases (ENOTTA)



George Kararigas
Professor
University of Iceland, Iceland

Patient stratification/precision medicine & how to structure further clinical research in Europe for IMiD with therapeutic antibodies



Alike Peletidi
Pharmacy Programme Coordinator, Lecturer in Applied Pharmacy Practice,
Pharmacy Programme, Department of Health Sciences
University of Nicosia, Cyprus

Personalized dosing, the cost-effectiveness of Therapeutic Drug Monitoring of biologics



Konstantin Tachkov
Assistant Professor
Faculty of Pharmacy, Medical University of Sofia

Precision dosing of biopharmaceutical in inflammatory diseases



David Ternant
Senior Lecturer
University of Tours, France

Track Overcoming Bioprocessing Challenges to go into Clinic

Session II

Innovative approaches to minimize the "QC tax" on Gene Therapy batch yield



Gael Debauxe
Head of Gene therapy CMC Analytics
UCB Pharma, Belgique

Leveraging Continuous Manufacturing to de-risk development from IND filing through to market supply



Nigel Shipston
Senior Director - Business Development
Just Evotec Biologics

Plasmid engineering technology from Polyplus: to fast track your rmAbs Discovery











Sylvain Julien
Director of Research Genetic Engineering
Polyplus, France

Working smart: rapid characterization of bispecific antibodies and agglutination process with FIDA



Marion Albasini
Business Developer
FidaBio, Denmark

THE 2023 AGENDA

15h20	<div>CAR T cells : overview of a revolution</div> <div><div></div><div></div><div><div>Elsa Kress</div><div>Head of Business Development</div><div>Mabdesign, France</div></div></div>
15h35	<div>Intellectual property and Biopharmaceuticals Round Table : Strategies to navigate an increasingly complex field</div> <div><div><div></div><div></div><div><div>Loïc Lemerrier</div><div>Associate and Head of IP & Technology</div><div>Dentons, France</div></div></div><div><div></div><div></div><div><div>Nicolas Bouquin</div><div>Senior Associate, European & French Partner Attorney</div><div>REGIMBEAU, France</div></div></div><div><div></div><div></div><div><div>Philippe Bessiere</div><div>Global Head of Patents</div><div>Pierre Fabre, France</div></div></div></div>
16h20	<div>Best Poster - Announcement of AIS2024</div>
16h30	<div>End of Congress</div>

2023 SCIENTIFIC ADVISORY BOARD



Alain Beck

Senior Director, Biologics CMC & developability
Centre d'Immunologie Pierre Fabre



Thierry Wurch

Senior Director, Global External Innovation and Partnering in Oncology
Evotec



Ana Antunes

Head of Scientific Events and Communication
MabDesign



Nicolas Poirier

Chief Scientific Officer
OSE Immunotherapeutics



Francis Duffieux

Principal Scientist, Head of Protein Purification, LMR Vitry
SANOI



Hervé Watier

Coordinator
LabEx Mabiimprove
Professor of Immunology
Faculty of Medicine of Tours
Head of Lab of Immunology
Univ. Hospital of Tours



Paul Parren

Executive VP and Head of R&D
Lava Therapeutics, Netherlands



Lennart Zabeau

Senior Research Scientist
Orionis Biosciences, Belgium



Hélène Negre

CMC Project Leader
SERVIER



Stéphanie Cornen

Director R&D
Innate Pharma



2023 SCIENTIFIC ADVISORY BOARD



Valentin Maison

Medical Doctor, Nephrologist

Service de néphrologie-hypertension artérielle, dialyses, transplantation rénale, CHU Bretonneau, Tours, France

SPHERE INSERM 1246, Université de Tours, Université de Nantes, Tours, France



Thibault Kervarrec

Pathologist

Department of Pathology University Hospital Center of Tours

"Biologie des infections à polyomavirus" team, INRAE UMR1282 ISP



Denis Mulleman

Professor


Department of Rheumatology, Nano Medicines & Nano Probes Research Group, Tours University



Béranger Largeau

Specialize Assistant Pharmacovigilance

CHRU Tours



Guillermo Carvajal Alegria

Attending Physician in Rheumatology

Hôpital Trousseau, Tours University



Yanis Ramdani

Researcher

Tours University



Pierre Boulard

Medical Intern

CHRU Tours



Roxane Lemoine

Research Engineer

Tours University



Philippe Gatault

Professor Assistant in Nephrology

T2I-Transplantation Immunology Inflammation, Tours University



Olivier Le Tilly

Researcher

Tours University

Join us in 2024



12th Antibody Industrial Symposium (AIS2024)

20-21 June 2024 in Montpellier, France

Ana Antunes

+33 (0)6 26 33 63 21

ana-sofia.antunes@mabdesign.fr



9th Bioproduction Congress (BIOPC2024)

25-26 September 2024 in Tours, France

Pierre-Mehdi Hammoudi

+33 (0)4 78 02 39 89

pierre-mehdi.hammoudi@mabdesign.fr



8th Immunotherapies & Innovations for Infectious Diseases Congress (I4ID2024)

November 2024 in Lyon, France

Laure Delhon

+33 (0)4 78 02 39 89

laure.delhon@mabdesign.fr